Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$545.11
+0.5%
$578.55
$432.96
$678.21
$33.12B0.37329,389 shs517,680 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$103.91
+0.9%
$106.65
$72.21
$139.13
$5.07B0.46670,196 shs399,410 shs
Azenta, Inc. stock logo
AZTA
Azenta
$32.85
+3.4%
$28.35
$23.91
$63.58
$1.45B1.64733,045 shs805,832 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$715.21
+1.2%
$609.88
$437.37
$718.73
$216.77B1.352.39 million shs2.91 million shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.42 million shsN/A
Vericel Corporation stock logo
VCEL
Vericel
$41.46
-0.3%
$41.63
$37.39
$63.00
$2.09B1.32417,193 shs405,371 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-1.59%-4.50%-5.94%-7.05%+24.93%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.36%-1.24%-1.86%-6.18%+27.08%
Azenta, Inc. stock logo
AZTA
Azenta
+3.18%+5.48%+18.86%-10.31%-37.77%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
-0.32%+6.72%+17.73%+25.16%+52.32%
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+59.33%
Vericel Corporation stock logo
VCEL
Vericel
-2.23%-4.01%-0.60%-6.12%-7.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.3132 of 5 stars
4.53.00.00.02.51.72.5
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.6769 of 5 stars
4.51.00.04.51.64.20.6
Azenta, Inc. stock logo
AZTA
Azenta
3.4904 of 5 stars
3.31.00.00.03.22.52.5
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.8482 of 5 stars
2.23.04.23.02.13.33.1
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.4678 of 5 stars
1.10.00.00.01.42.50.6
Vericel Corporation stock logo
VCEL
Vericel
2.8767 of 5 stars
3.51.00.00.03.10.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.05
Buy$729.9333.91% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3365.85% Upside
Azenta, Inc. stock logo
AZTA
Azenta
2.50
Moderate Buy$50.6754.24% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.33
Hold$603.73-15.59% Downside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1447.47% Upside

Current Analyst Ratings Breakdown

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$630.00 ➝ $715.00
7/1/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
6/24/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/23/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$570.00 ➝ $592.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/12/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.00
6/11/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/10/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
6/10/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
6/9/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$153.00 ➝ $150.00
6/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$185.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B14.78$2.98 per share182.62$90.49 per share6.02
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.27N/AN/A$1.18 per share88.06
Azenta, Inc. stock logo
AZTA
Azenta
$656.32M2.29$4.71 per share6.98$36.16 per share0.91
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$126.85B1.73$54.35 per share13.16$350.27 per share2.04
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.80$0.31 per share133.12$5.92 per share7.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$16.2133.6350.240.9840.20%16.15%14.33%7/24/2025 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A36.85N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
Azenta, Inc. stock logo
AZTA
Azenta
-$164.17M-$1.39N/A35.71N/A-10.31%1.30%1.10%8/5/2025 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.28B$43.0916.6013.740.9611.86%13.76%0.87%7/16/2025 (Estimated)
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,382.4694.23N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.87N/AN/AN/A$776.82 millionN/A
7/16/2025Q2 2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$9.82N/AN/AN/A$13.53 billionN/A
5/8/2025Q1 2025
argenex SE stock logo
ARGX
argenex
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/7/2025Q2 2025
Azenta, Inc. stock logo
AZTA
Azenta
$0.09$0.05-$0.04-$0.89$140.87 millionN/A
4/14/2025Q1 2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.57$14.12+$1.55$14.12$14.99 billion$15.06 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Azenta, Inc. stock logo
AZTA
Azenta
N/AN/AN/AN/AN/A
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.001.68%N/A27.85%13 Years
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$3.002.3%5/30/20255/30/20256/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
7.29
6.68
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
Azenta, Inc. stock logo
AZTA
Azenta
N/A
3.22
2.84
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.41
0.68
0.68
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Azenta, Inc. stock logo
AZTA
Azenta
99.08%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.30%
Azenta, Inc. stock logo
AZTA
Azenta
10.62%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.06 million59.58 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.26 millionOptionable
Azenta, Inc. stock logo
AZTA
Azenta
3,30045.78 million40.92 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
46,500306.84 million305.15 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million47.73 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$545.11 +2.64 (+0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$550.00 +4.89 (+0.90%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$103.91 +0.94 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$104.00 +0.09 (+0.08%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Azenta stock logo

Azenta NASDAQ:AZTA

$32.85 +1.09 (+3.43%)
Closing price 04:00 PM Eastern
Extended Trading
$32.86 +0.01 (+0.02%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$715.21 +8.75 (+1.24%)
Closing price 03:59 PM Eastern
Extended Trading
$716.00 +0.79 (+0.11%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Inari Medical stock logo

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)
As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$41.46 -0.14 (-0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$41.44 -0.02 (-0.05%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.